MedTrace Logo

Ranibizumab as a Rescue Therapy for Diabetic Macular Edema

NCT01253694 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-05-03

No results posted yet for this study

Summary

Treatment with Ranibizumab of the residual diabetic edema in patients with failed response to Bevacizumab.

Conditions

Interventions

DRUG

injection of 0.5 mg of Intravitreal Ranibizumab

Following the sterile technique, intravitreal injection of anti-VEGF is applied

Sponsors & Collaborators

  • New England Retina Associates

    lead OTHER

Principal Investigators

  • Nauman Chaudhry, MD · New England Retina Associates

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2012-06-30
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01253694 on ClinicalTrials.gov